Alcohol ( DrugBank: Alcohol )
4 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 58 | 肥大型心筋症 | 7 |
| 279 | 巨大静脈奇形（頚部口腔咽頭びまん性病変） | 1 |
| 298 | 遺伝性膵炎 | 5 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00220922 (ClinicalTrials.gov) | August 2004 | 20/9/2005 | A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®. | An Open-Label, Randomized, Single Cross-Over Study of Isopropyl Alcohol Wipes Versus No Injection Site Preparation on Local Injection Site Reactions Among Persons With Multiple Sclerosis Who Perform Daily Injections of Copaxone® | Multiple Sclerosis | Procedure: Alcohol Wipes vs. No Alcohol Wipes | Teva Neuroscience, Inc. | NULL | Completed | 18 Years | N/A | Both | 50 | Phase 4 | United States |
58. 肥大型心筋症
臨床試験数 : 119 / 薬物数 : 163 - (DrugBank : 45) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 161
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04684290 (ClinicalTrials.gov) | June 30, 2021 | 16/11/2020 | Surgical Septal Myectomy vs Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy | Surgical Septal Myectomy Versus Percutaneous Transluminal Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy | Hypertrophic Cardiomyopathy | Procedure: Alcohol Septal Ablation;Procedure: Surgical Septal Myectomy | St. Antonius Hospital | Erasmus Medical Center | Recruiting | 40 Years | 75 Years | All | 100 | N/A | Netherlands |
| 2 | ChiCTR2000041464 | 2021-01-01 | 2020-12-26 | The efficacy after alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy: a retrospective study based on medical records | The efficacy after alcohol septal ablation in mildly symptomatic patients with hypertrophic obstructive cardiomyopathy | hypertrophic obstructive cardiomyopathy | alcohol septal ablation group vs medical treatment group :Nil; | Beijing Anzhen Hospital, Capital Medical University | NULL | Recruiting | 18 | 80 | Both | alcohol septal ablation group vs medical treatment group :200; | China | |
| 3 | ChiCTR2000033626 | 2020-06-01 | 2020-06-07 | Endocardial Radiofrequency Septal Ablation Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy | Endocardial Radiofrequency Septal Ablation Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: a Randomized, Controlled, Open-Label Non-Inferiority Study | Hypertrophic Obstructive Cardiomyopathy | diofrequency ablation:radiofrequency ablation;Alcohol Ablation:Alcohol Septal Ablation; | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | NULL | Recruiting | 18 | 75 | Both | diofrequency ablation:40;Alcohol Ablation:40; | China | |
| 4 | NCT04133532 (ClinicalTrials.gov) | March 5, 2020 | 16/10/2019 | Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy | Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy | Hypertrophic Cardiomyopathy | Drug: Metoprolol | University Hospital, Motol | NULL | Recruiting | 18 Years | 75 Years | All | 50 | Phase 4 | Czechia |
| 5 | NCT04066777 (ClinicalTrials.gov) | May 29, 2019 | 22/8/2019 | The Effect of TASH in Patients With HOCM | The Effect of Alcohol Septal Ablation Theraphy on Left Ventricular Function and Invasive Hemodynamics at Rest and During Exercise in Patients With Hypertrophic Obstructive Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Procedure: alcohol septal ablation | Steen Hvitfeldt Poulsen | NULL | Recruiting | 18 Years | N/A | All | 24 | N/A | Denmark |
| 6 | NCT02674958 (ClinicalTrials.gov) | May 2016 | 6/1/2016 | Mobilization of Endothelial Progenitor Cells and Aspirin | Mobilization of Endothelial Progenitor Cells Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Randomized Controlled Trial of Aspirin | Hypertrophic Obstructive Cardiomyopathy | Drug: Aspirin | Ottawa Heart Institute Research Corporation | NULL | Recruiting | 18 Years | 80 Years | All | 20 | Phase 3 | Canada |
| 7 | NCT00035386 (ClinicalTrials.gov) | April 2002 | 2/5/2002 | Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study | Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study | Hypertrophic Cardiomyopathy | Procedure: trans-right ventricular alcohol septal ablation (TRVASA) | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | N/A | N/A | Both | 12 | Phase 2 | United States |
279. 巨大静脈奇形（頚部口腔咽頭びまん性病変）
臨床試験数 : 14 / 薬物数 : 24 - (DrugBank : 9) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-011276-29-FR (EUCTR) | 21/08/2009 | 15/05/2009 | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study. | patients with congenital venous malformations (CVM) | Product Name: Ethanol gel Product Code: L0122 Other descriptive name: ETHANOL (96 PER CENT) Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection Other descriptive name: ETHANOL BP | ORFAGEN | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 24 | France |
298. 遺伝性膵炎
臨床試験数 : 98 / 薬物数 : 180 - (DrugBank : 57) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02965898 (ClinicalTrials.gov) | September 2016 | 23/9/2016 | The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis | The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial | Chronic Pancreatitis | Dietary Supplement: Vitamin D 100ug;Dietary Supplement: Vitamin D 10ug | Tampere University Hospital | Orion Corporation, Orion Pharma | Recruiting | 18 Years | 101 Years | All | 260 | N/A | Finland |
| 2 | NCT02487225 (ClinicalTrials.gov) | May 2015 | 29/6/2015 | Pentoxifylline Treatment in Acute Pancreatitis (AP) | Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial | Acute Pancreatitis (AP);Gallstone Pancreatitis;Alcoholic Pancreatitis;Trauma Acute Pancreatitis;Hypertriglyceridemia Acute Pancreatitis;Idiopathic (Unknown) Acute Pancreatitis;Medication Induced Acute Pancreatitis;Cancer Acute Pancreatitis;Miscellaneous (i.e. Acute on Chronic Pancreatitis) | Drug: Pentoxifylline;Drug: Placebo | Mayo Clinic | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | 18 Years | 100 Years | All | 83 | Phase 3 | United States |
| 3 | NCT04574297 (ClinicalTrials.gov) | January 1, 2011 | 27/9/2020 | An Observational Study on the Natural Course of Chronic Pancreatitis | The Impact of Genetic and Environmental Factors on the Progression of Chronic Pancreatitis:An Observational Study | Chronic Pancreatitis;Genetic Mutation;Smoking, Tobacco;Drinking, Alcohol | Behavioral: smoking and alcohol assumption;Diagnostic Test: genetic sequencing | Changhai Hospital | NULL | Active, not recruiting | N/A | N/A | All | 965 | NULL | |
| 4 | NCT00782795 (ClinicalTrials.gov) | November 2008 | 29/10/2008 | Chronic Pancreatitis. Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality | Phase II Study of Chronic Pancreatitis and the Effect of Pioglitazone on Endocrine Function, Exocrine Function & Structure, Pain & Life Quality | Chronic Pancreatitis;Insulin Resistance;Normal or Mildly Abnormal Stool Fat Levels | Drug: Pioglitazone;Drug: Placebo | University of Michigan | National Institute on Alcohol Abuse and Alcoholism (NIAAA);Takeda Pharmaceuticals North America, Inc. | Completed | 18 Years | 75 Years | All | 64 | Phase 2 | United States |
| 5 | NCT00583271 (ClinicalTrials.gov) | June 2002 | 20/12/2007 | A Prospective Study of EUS Guided Celiac Block | A Prospective Study of Endoscopic Ultrasound-guided Celiac (CB) Effectiveness | Chronic Pancreatitis;Pancreatic Cancer | Drug: triamcinolone;Drug: 98% dehydrated alcohol | Indiana University | NULL | Completed | 18 Years | N/A | Both | 127 | N/A | United States |